Abstract
Several studies have indicated that the in vivo binding of D2 receptor positron emission tomography radiotracers can, under some conditions, be influenced by competition with endogenous dopamine. The present study was undertaken to compare the extent to which the in vivo binding in mice of radiotracers to other amine neuroreceptors, namely D1, 5-HT2A and 5-HT1A receptors, can also be modulated by neurotransmitter competition. For dopamine radiotracers we examined [3H]raclopride as a D2 radiotracer and [3H]A69024 as a D1 radiotracer. Striatal binding of both radiotracers was substantially reduced by administration of the dopamine releaser, amphetamine, although only at a high dose. [3H]raclopride was decreased more than [3H]A69024. Dopamine depletion with 4-hydroxybutyrate strongly increased [3H]raclopride binding but failed to increase [3H]A69024 binding. For 5-HT radiotracers we examined [3H]N-methylspiperone as a 5-HT2A radiotracer and [3H]WAY 100635 as a 5-HT1A radiotracer. Cortical binding of both radiotracers was unaffected by the 5-HT releaser, p-chloroamphetamine. [3H]WAY 100635 binding was additionally unaffected by 5-HT release with fenfluramine and by 5-HT depletion with p-chlorophenylalanine.
In conclusion, of the four radiotracers examined, [3H]raclopride binding to D2 receptors had greatest sensitivity to changes in endogenous neurotransmitter levels. [3H]A69024 binding to D1 receptors was affected only by neurotransmitter increases. [3H]N-methylspiperone binding to 5-HT2A receptors and [3H]WAY 100635 binding to 5-HT1A receptors appeared insensitive to changes in neurotransmitter levels.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea-Ponce Y, Lombardo I, van Heertum R, Mann JJ, Foged C, Halldin C, Laruelle M . (1999): PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse 32: 93–109
Andersen PH, Gronvald FC, Jansen JA . (1985): A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum. Life Sci 37: 1971–1983
Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A . (1984): Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci 35: 1885–1893
Carson RE, Breier A, de Bartolomeis A, Saunders RC, Su TP, Schmall B, Der MG, Pickar D, Eckelman WC . (1997): Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 17: 437–447
Carson RE, Lang L, Watabe H, Der MG, Adams HR, Jagoda E, Herscovitch P, Eckelman WC . (2000): PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. Nucl Med Biol 27: 493–497
Crespi D, Mennini T, Gobbi M . (1997): Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p- chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121: 1735–1743
Farde L, Ginovart N, Ito H, Lundkvist C, Pike VW, McCarron JA, Halldin C . (1997): PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain. Psychopharmacology 133: 196–202
Farde L, Halldin C, Stone-Elander S, Sedvall G . (1987): PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology 92: 278–284
Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, Fletcher A . (1995): A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 281: 81–88
Frost JJ, Smith AC, Kuhar MJ, Dannals RF, Wagner HN Jr . (1987): In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors. Life Sci 40: 987–995
Gatley SJ, Gifford AN, Carroll FI, Volkow ND . (2000): Sensitivity of binding of high-affinity dopamine receptor radioligands to increased synaptic dopamine. Synapse 38: 483–488
Gifford AN, Gatley SJ, Volkow ND . (1998): Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high-affinity PET and SPECT radiotracers. Synapse 28: 167–175
Gifford AN, Park MH, Kash TL, Herman LM, Park E-H, Gatley SJ, Volkow ND . (2000): Effect of amphetamine-induced dopamine release on radiotracer binding to D1 and D2 receptors in rat brain striatal slices. Naunyn-Schmiedeberg's Arch Pharmacol 362: 413–418
Ginovart N, Hassoun W, Le Bars D, Weissmann D, Leviel V . (2000): In vivo characterization of p-[(18)F]MPPF, a fluoro analog of WAY-100635 for visualization of 5-HT(1a) receptors. Synapse 35: 192–200
Gobbi M, Parazzoli A, Mennini T . (1998): In vitro studies on the mechanism by which (+)-norfenfluramine induces serotonin and dopamine release from the vesicular storage pool. Naunyn-Schmiedeberg's Arch Pharmacol 358: 323–327
Halldin C, Foged C, Farde L, Karlsson P, Hansen K, Gronvald F, Swahn CG, Hall H, Sedvall G . (1993): [11C]NNC 687 and [11C]NNC 756, dopamine D-1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. Nucl Med Biol 20: 945–953
Halldin C, Stone-Elander S, Farde L, Ehrin E, Fasth KJ, Langstrom B, Sedvall G . (1986): Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int J Rad Appl Instrum [A] 37: 1039–1043
Innis RB, Malison RT, al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, Zoghbi SS, Baldwin RM, Laruelle M, Smith EO . (1992): Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse 10: 177–184
Inoue O, Tsukada H, Yonezawa H, Suhara T, Langstrom B . (1991): Reserpine-induced reduction of in vivo binding of SCH 23390 and N-methylspiperone and its reversal by d-amphetamine. Eur J Pharmacol 197: 143–149
Kassiou M, Mathews WB, Musachio JL, Ravert HT, Lambrecht RM, Dannals RF . (1994): Radiosynthesis of (2-bromo-4, 5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-[11C]-methyl-1,2,3,4-tetrahydroisoquinoline, [11C]A-69024: a non-benzazepine antagonist for studying dopamine D1 receptors in vivo using PET. J Labelled Compds Radiopharm 34: 431–437
Kassiou M, Scheffel U, Ravert HT, Mathews WB, Musachio JL, Lambrecht RM, Dannals RF . (1995): [11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. Nucl Med Biol 22: 221–226
Kerkman DJ, Ackerman M, Artman LD, MacKenzie RG, Johnson MC, Bednarz L, Montana W, Asin KE, Stampfli H, Kebabian JW . (1989): A-69024: a non-benzazepine antagonist with selectivity for the dopamine D-1 receptor. Eur J Pharmacol 166: 481–491
Khawaja X, Evans N, Reilly Y, Ennis C, Minchin MC . (1995): Characterisation of the binding of [3H]WAY-100635, a novel 5-hydroxytryptamine-1A receptor antagonist, to rat brain. J Neurochem 64: 2716–2726
Kohler C, Hall H, Ogren SO, Gawell L . (1985): Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34: 2251–2259
Kuczenski R, Segal DS . (1992): Differential effects of amphetamine and dopamine uptake blockers (cocaine, nomifensine) on caudate and accumbens dialysate dopamine and 3-methoxytyramine. J Pharmacol Exp Ther 262: 1085–1094
Kung HF, Pan S, Kung MP, Billings J, Kasliwal R, Reilley J, Alavi A . (1989): In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 30: 88–92
Laruelle M . (2000): Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20: 423–451
Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF . (1995): SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36: 1182–1190
Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW . (1997): Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25: 1–14
Lyon RA, Titeler M, Frost JJ, Whitehouse PJ, Wong DF, Wagner HN Jr, Dannals RF, Links JM, Kuhar MJ . (1986): 3H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex. J Neurosci 6: 2941–2949
Mennini T, Bizzi A, Caccia S, Codegoni A, Fracasso C, Frittoli E, Guiso G, Padura IM, Taddei C, Uslenghi A . (1991): Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs. Naunyn-Schmiedeberg's Arch Pharmacol 343: 483–490
Morgan AE, Porter SP, Clarkson FA, Volkow ND, Fowler JS, Dewey SL . (1997): Direct approach for attenuating cocaine's effects on extracellular dopamine: targeting the dopamine transporter. Synapse 26: 423–427
Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B . (1993): 5-HT2 and D2 dopamine receptor occupancy in the living human brain: A PET study with risperidone. Psychopharmacology 110: 265–272
Pike VW, McCarron JA, Lammertsma AA, Osman S, Hume SP, Sargent PA, Bench CJ, Cliffe IA, Fletcher A, Grasby PM . (1996): Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. Eur J Pharmacol 301: R5–R7
Plenevaux A, Weissmann D, Aerts J, Lemaire C, Brihaye C, Degueldre C, Le Bars D, Comar D, Pujol J, Luxen A . (2000): Tissue distribution, autoradiography, and metabolism of 4-(2′-methoxyphenyl)-1-[2′ -[N-(2′′-pyridinyl)-p-[(18)F]fluorobenzamido]ethyl]piperazine (p-[(18)F]MPPF), a new serotonin 5-HT(1A) antagonist for positron emission tomography: An in vivo study in rats. J Neurochem 75: 803–811
Raiteri M, Bonanno G, Vallebuona F . (1995): In vitro and in vivo effects of d-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia. J Pharmacol Exp Ther 273: 643–649
Ross SB . (1991): Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem 56: 22–29.
Ross SB, Jackson DM . (1989a): Kinetic properties of the accumulation of 3H-raclopride in the mouse brain in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 340: 6–12.
Ross SB, Jackson DM . (1989b): Kinetic properties of the in vivo accumulation of 3H-(-)-N-n- propylnorapomorphine in mouse brain. Naunyn-Schmiedeberg's Arch Pharmacol 340: 13–20.
Swart JA, van der Werf JF, Wiegman T, Paans AM, Vaalburg W, Korf J . (1990): In vivo binding of spiperone and N-methylspiperone to dopaminergic and serotonergic sites in the rat brain: multiple modeling and implications for PET scanning. J Cereb Blood Flow Metab 10: 297–306.
Thibaut F, Vaugeois JM, Bonnet JJ, Costentin J . (1996): In vivo striatal binding of the D1 antagonist SCH 23390 is not modified by changes in dopaminergic transmission. Neuropharmacology 35: 267–272.
Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C, Hitzemann R, Pappas NR . (1999): Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 291: 409–415.
Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, MacGregor R . et al. (1994): Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 16: 255–262.
Wang GJ, Volkow ND, Logan J, Fowler JS, Schlyer D, MacGregor RR, Hitzemann RJ, Gur RC, Wolf AP . (1995): Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life Sci 56: L249–L253.
Young LT, Wong DF, Goldman S, Minkin E, Chen C, Matsumura K, Scheffel U, Wagner HN Jr . (1991): Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain. Synapse 9: 188–194.
Acknowledgements
Supported by National Institute of Health grant R01DA/NS11552-01. This research was performed at the Brookhaven National Laboratory under contract DE-AC02-98CH10886 with the U.S. Department of Energy and supported by the Office of Health and Environmental Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rice, O., Gatley, S., Shen, J. et al. Effects of Endogenous Neurotransmitters on the in vivo Binding of Dopamine and 5-HT Radiotracers in Mice. Neuropsychopharmacol 25, 679–689 (2001). https://doi.org/10.1016/S0893-133X(01)00287-1
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(01)00287-1
Keywords
This article is cited by
-
PET imaging reveals brain functional changes in internet gaming disorder
European Journal of Nuclear Medicine and Molecular Imaging (2014)
-
Measurement of 5-HT1A Receptor Density and in-vivo Binding Parameters of [18F]mefway in the Nonhuman Primate
Journal of Cerebral Blood Flow & Metabolism (2012)
-
Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls
Journal of Cerebral Blood Flow & Metabolism (2010)
-
Occupancy of Agonist Drugs at the 5-HT1A Receptor
Neuropsychopharmacology (2004)
